

# Plasmon-Activated Water Decreases Vasculopathy in Orthotopic Allograft Transplantation Rats

**Chien-Sung Tsai**

National Defense Medical Center

**Yi-Wen Lin**

National Yang Ming University

**Chun-Min Shih**

Taipei Medical University

**Yi-Ting Tsai**

National Defense Medical Center

**Chun-Yao Huang**

Taipei Medical University

**Shing-Jong Lin**

Taipei Heart Institute

**Chi-Yuan Li**

China Medical University

**Cheng-Yen Lin**

Ming Chuan University

**Hong-Ta Tseng**

Taipei Medical University

**Yu-Chuan Liu**

Taipei Medical University

**Feng-Yen Lin** (✉ [g870905@tmu.edu.tw](mailto:g870905@tmu.edu.tw))

Taipei Medical University

---

## Research Article

**Keywords:** orthotopic allograft transplantation, vasculopathy, plasmon-activated water.

**Posted Date:** December 28th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-125516/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

# Abstract

Patients undergoing orthotopic allograft transplantation (OAT) will certainly suffer from vasculopathy. Although there are many immunosuppressive and immunomodulatory agents that are administered to patients, chronic rejection-induced vasculopathy cannot be entirely managed. Moreover, the implanted graft might become dysfunctional. In the past, we have used deionized reverse osmosis water (ROW) to stream via gold nanoparticles (AuNPs) at room temperature under powerful illumination, in order to prepare plasmon-activated water (PAW) with fewer hydrogen bonds. Compared to ROW, stable PAW can successfully remove free hydroxyl and 2,2-diphenyl-1-picrylhydrazyl radicals, and efficiently reduce lipopolysaccharide (LPS)-induced monocytes to release nitric oxide. Moreover, PAW can considerably induce the expression of the antioxidant gene Nrf2 in human gingival fibroblasts. Moreover, it might lower amyloid burden in mice with Alzheimer's disease. Furthermore, PAW decreased metastasis in mice grafted with Lewis lung carcinoma cells and boosted the overall survival in combination with cisplatin. Because of this possibility that PAW could prevent systemic disease, we aimed to evaluate the influence of PAW on OAT-induced vasculopathy. Here, we demonstrated that daily intake of PAW lowered the progression of vasculopathy in OAT-recipient ACI/NKyo rats by inhibiting collagen accumulation, proliferation of smooth muscle cells and fibroblasts, and T lymphocyte infiltration in the vessel wall. Moreover, the results showed reduced T and B lymphocytes, plasma cells, and macrophage activation in the spleen of the OAT-recipient ACI/NKyo rats that were administered PAW. Finally, in contrast to the control group, the OAT-recipient ACI/NKyo rats that were administered PAW exhibited higher mobilization and levels of circulating endothelial progenitor cells associated with vessel repair. Therefore, this study highlights the therapeutic roles of PAW in vasculopathy.

## Introduction

Orthotopic allograft transplantation (OAT) is the main treatment method for end-stage organ failure. Since the currently available clinical strategies can effectively control acute rejection, short-term survival rate of patients after organ transplantation has greatly improved. However, presently, the main factor affecting the long-term survival of patients undergoing organ transplantation is chronic rejection. Chronic rejection is a process in which the alloimmune system attacks the donor graft, and causes continuous and diffused damage of the vessels, resulting in vasculopathy<sup>1</sup>. The targets of this alloimmune system attack include the epithelium and endothelium of the implanted graft. Arteries and microvessels, which cause the original normal parenchyma to be replaced by fibrotic scar, exhibit the hyperplasia of vascular intimal fibrosis that causes diffuse occlusion and narrowing of the vessels implanted in the graft<sup>2</sup>. Eventually, progressive arterial fibrosis and constriction will lead to organ ischemia, with the lesions leading to organ failure in patients after transplantation<sup>3</sup>. Therefore, OAT-induced vasculopathy is an important problem after organ transplantation that needs to be resolved.

The occurrence of chronic rejection after OAT is indeed related to the production of antibodies against donor-specific human leukocyte antigen (HLA) by the recipient<sup>4</sup>. Since OAT-induced vasculopathy only

occurs in the vessels of the donor grafts that are transplanted, but not in the native vessels of the recipients, alloimmunity is currently considered to be the main cause of OAT-induced vasculopathy<sup>2</sup>. Donor antigen-presenting cells present in the donor organ, such the MHC molecules on the surface of dendritic cells, will be recognized by the recipient's T cells, which, in turn, results in the activation of the cellular immune response. In addition, the donor antigen fragments presented on the surface of the recipient's antigen-presenting cells will be recognized by the recipient's T cells<sup>3</sup>. This process is the main initiator of the immune response responsible for chronic rejection<sup>5</sup>. The activated T cells will release interleukin-2 (IL-2) and interferon- $\gamma$  (IFN- $\gamma$ ). These cytokines will continue to activate the T cells, B cells, and macrophages, and additionally, the graft vascular endothelial cells will also be activated and will begin to express several vascular cell adhesion molecules. This process causes an increased number of recipient immune cells to be chemoattracted to the vascular endothelium of the donor graft, thereby amplifying the immune response<sup>6</sup>. The smooth muscle cells are also activated simultaneously, resulting in their proliferation<sup>7</sup>, the secretion and accumulation of extracellular matrix proteins, and concomitantly, the activated B cells produce anti-HLA antibodies, which combine with macrophages to jointly regulate the vascular damage of the implanted graft. Therefore, the damage after OAT, resulting from both T cell-associated cellular immune responses and B cell-associated humoral immune responses<sup>5</sup>, eventually leads to vascular intimal hyperplasia, fibrosis<sup>8</sup>, ischemia, and functional failure of the implanted graft<sup>9</sup>.

Plasmon-activated water (PAW) is produced by allowing deionized reverse osmosis water (ROW) to flow through gold nanoparticles (AuNPs) under resonant illumination, which excites the hot electron transfer provided by AuNPs and destroys the hydrogen bonds between H<sub>2</sub>O<sup>10,11</sup>. Compared with ROW, PAW has higher physical and chemical activity, including greater solubility for alkali metal-chloride salts, increased ionic conductivity of NaCl, higher extraction efficiency of biological antioxidants, such as polyphenols, 2,3,5,4'-tetrahydroxystilbene-2-O-beta-d-glucoside (THSG) and polygonum multiflorum<sup>12</sup>. Intracellular ROS production and ROS-activated signaling are closely associated with the development of cancers, autoimmune diseases, and systemic inflammatory diseases. In recent years, scientists have found that PAW might reduce ROS-induced cellular and tissue damage mediated by various mechanisms<sup>13</sup>. In addition, PAW can inhibit the lipopolysaccharide (LPS)-induced production of nitric oxide (NO) by monocytic cells, thereby inhibiting oxidative stress during acute inflammatory responses<sup>10</sup>. It might also activate the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2 related factor 2 (Nrf2)/antioxidant response element (ARE) pathway and increase the antioxidant capacity of human gingival fibroblasts. Additionally, the administration of PAW may increase the survival rate of non-small cell lung cancer (NSCLC)-bearing mice that are administered cisplatin and reduce the metastasis of NSCLCs<sup>14</sup>. Furthermore, it might also reduce the myeloid burden in neurons and improve memory as well as decrease the severity of Alzheimer's disease in APP<sup>swe</sup>/PSEN1<sup>dE9</sup> transgenic mice<sup>15</sup>.

Because PAW is safe, easily produced, and inexpensive, it should be a publicly accessible and an feasible option. Based on our previous findings regarding the effectiveness of PAW in the treatment of inflammation-related diseases, we planned to further evaluate the effect of PAW on the occurrence of

OAT-induced vasculopathy. In this study, we transplanted the thoracic aorta of PVG/Seac rats into the abdominal aorta of ACI/NKyo rats and compared the severity of vasculopathy after 30–150 days of OAT in animals that were administered ROW and PAW. We also compared the chronic rejection situation of animals in the two groups by immunohistochemical analysis of the spleen and explored the underlying mechanisms of OAT-induced vasculopathy. We expect that this study will enhance the applicability of PAW in the prevention and treatment of inflammatory diseases in the future.

## Results

### Administration of PAW did not affect the biochemical characteristics in OAT ACI/NKyo rats

Biochemical analyses were performed to evaluate the effects of PAW on OAT ACI/NKyo rats. As shown in Table 1, body weight change, BUN, creatinine, ALT, and AST did not differ among the groups during the experimental period.

Table 1  
Comparison of Biochemical Parameters in Experimental ACI//NKyo Rats.

	Control ACI/NKyo (non-OAT)		OAT + ROW (PVG/Seac to ACI/NKyo)		OAT + PAW (PVG/Seac to ACI/NKyo)	
	baseline	90 days	baseline	90 days	baseline	90 days
<b>Body weight (g)</b>	240.3 ± 18.6	350.1 ± 16.7	220.9 ± 12.8	332.5 ± 15.6	234.6 ± 10.2	365.7 ± 13.4
<b>BUN (mg/dL)</b>	26.5 ± 5.6	30.0 ± 5.9	26.8 ± 9.0	29.5 ± 6.1	25.4 ± 7.1	29.8 ± 6.8
<b>Creatinine (mg/dL)</b>	0.6 ± 0.1	0.7 ± 0.2	0.8 ± 0.5	0.8 ± 0.3	0.9 ± 0.3	0.9 ± 0.2
<b>ALT (IU/L)</b>	19.9 ± 6.7	22.8 ± 9.1	21.3 ± 6.5	23.5 ± 9.1	25.4 ± 3.8	20.6 ± 1.9
<b>AST (IU/L)</b>	30.5 ± 6.1	32.5 ± 8.1	30.5 ± 3.6	30.6 ± 8.1	29.8 ± 9.9	30.5 ± 9.1

OAT, orthotopic aortic transplantation; BW, body weight; BUN, blood urea nitrogen; ALT, alanine transaminase; AST, aspartate transaminase; Values are represented as mean ± SD. <sup>a</sup> $p < 0.05$  compared with baseline of the same group; <sup>b</sup> $p < 0.05$  compared with Control ACI/NKyo (non-OAT) group at the same time point; <sup>c</sup> $p < 0.05$  compared with OAT + ROW (PVG/Seac to ACI/NKyo) group at the same time point. Statistical evaluations were performed using one-way ANOVA.

### PAW decreases vasculopathy and collagen accumulation in OAT ACI/NKyo rats

Representative photographs of vasculopathy in the thoracic aortas (from donor PVG/Seac rats) stained with H&E were shown in Fig. 1A, and the quantifications of intima/vessel wall area ratio are shown in Fig. 1B. No vasculopathy signs were observed in the aortas of normal PVG/Seac rats. Severe damage to vascular integrity, blurred elastin laminae, and accumulation of calcified plaques were markedly increased in the OAT group compared to normal vessels in PVG/Seac rats (Fig. 1A). Additionally, the formation of an incomplete vascular structure correlated with time (from day 30 to day 90) in the OAT group. A significantly smaller area of aortic vasculopathy and greater vascular integrity were observed in the OAT plus PAW group compared to that of the OAT plus ROW group on day 90. Interestingly, the vessel wall remained intact in addition to slight neointimal formation at day 150 after OAT, and there was no calcified plaque formation.

Vasculopathy has been implicated in the development of collagen accumulation<sup>16</sup>. Therefore, picrosirius red staining was performed for visualizing collagen. As shown in Fig. 1C, normal thoracic aortas from PVG/Seac rats presented intact, thick collagen fibers (weak orange to red) and an equal distribution of fine collagen fibers (yellow to green) in the vessel walls. In contrast, the vessels in the OAT with ROW group at day 90 appeared to exhibit wall thickening in the inner layer, with some of the fine collagen fibers being piled up with a small amount of messy, thick collagen fibers. Moreover, the thick collagen fibers in the original vessel walls became inconsistent in thickness. However, in the OAT with PAW group, the disordered distribution and accumulation of fine and thick collagen fibers indeed improved significantly compared to that of the OAT with ROW group at day 90. The vessel wall showed reduced collagen accumulation which lasted up to day 120 and day 150 in the OAT plus PAW group.

### **Reduced proliferation and accumulation of immune cells was observed in the vessel wall of PAW administered OAT ACI/NKyo rats**

Proliferation of SMCs and fibroblasts plays a critical role in the process of chronic allograft vasculopathy. Therefore, immunohistochemical staining was performed using antibodies against  $\alpha$ SMA and S100A4 on transplanted aorta sections (Fig. 2A). The OAT PVG/Seac thoracic aorta sections at day 90 showed marked accumulation of SMCs and fibroblasts in hyperplasia area on the luminal surface in ROW administered group compared to sections of the PAW administered group. CD4- and CD8-positive T cells are subtypes of lymphocytes. CD4-positive T cells are MHC class II-restricted and CD8-positive T cells are a critical subpopulation of regulatory T-lymphocytes involved in MHC class I-restricted interactions, and hence they are important mediators of adaptive immunity. Infiltrated CD11b positive macrophages also play critical roles in the process of chronic allograft vasculopathy. Therefore, immunohistochemical staining was performed on transplanted aorta sections to identify the immune reaction in the vessel using antibodies against CD4, CD8, and CD11b (Fig. 2B). The thoracic aorta sections from the OAT PVG/Seac ROW administered group at day 90 showed marked infiltration of CD4-, CD8-, and CD11b-positive cells. However, T lymphocytes and macrophages were accumulated less in the vessel wall in PAW administered group. These results indicated that relatively minimal adaptive immune reactions occurred in the vessel wall of the PAW administered group, resulting in reduced T lymphocyte and macrophage infiltration.

## Administration of PAW results in lower plasma concentration of inflammatory factors and cytokines in OAT ACI/NKyo rats

As shown in Table 2, inflammation-related cytokines and markers were produced in the plasma. LDH is an enzyme that is released into the plasma following tissue injury, and might be strongly associated with antibody-mediated rejection<sup>17</sup>. Elevated plasma levels of LDH were observed in OATACI/NKyo rats administered with ROW; higher LDH levels ( $1888.78 \pm 323.0$  IU/L) compared to the baseline ( $854.6 \pm 152.5$  IU/L) were observed in the ROW group; the level of LDH was significantly higher than that of the non-OAT group ( $895.9 \pm 125.6$  IU/L) at day 90. However, the elevated LDH level was decreased in the OAT plus PAW group ( $968.8 \pm 116.4$  IU/L) at day 90. CRP is an indicator of inflammation and tissue damage<sup>18</sup> and HMGB1 is involved in the chronic rejection of cardiac allograft vasculopathy<sup>19</sup>. As shown in Table 2, the CRP levels were increased after 90 days of OAT compared to the baseline in ROW ( $163.5 \pm 22.5$  mg/dL) or PAW ( $72.1 \pm 5.4$  mg/dL) plus OAT groups. Nevertheless, after OAT, PAW administered rats still had relatively low levels of CRP compared to the rats administered with ROW. Similar to CRP levels, the HMGB1 expression was lower in rats in the PAW group than that in ROW group. Additionally, the function of EPCs is related to the occurrence of OAT-induced vasculopathy<sup>20</sup>. However, SDF-1 $\alpha$  is involved in the homing and recruitment of EPCs, and TGF- $\beta$ 1 negatively regulates EPC function<sup>21</sup> following OAT. Regardless of whether the rats received ROW or PAW, OAT increased plasma SDF-1 $\alpha$  and TGF- $\beta$ 1 levels. Especially, administration of PAW resulted in a significant SDF-1 $\alpha$  increase ( $1211.4 \pm 130.2$  pg/mL) and TGF- $\beta$ 1 decrease ( $129.7 \pm 54.1$  ng/mL) at day 90 compared to that of the OAT plus ROW group ( $432.6 \pm 100.4$  pg/mL for SDF-1 $\alpha$  and  $378.1 \pm 55.9$  ng/mL for TGF- $\beta$ 1). IFN- $\gamma$  mediates transplant vasculopathy through CD8<sup>+</sup> or CD4<sup>+</sup> T lymphocyte-associated injury of vascular endothelial cells. Furthermore, cytokines such as IL-2 cause a reversible insult to the endothelium around the time of transplantation<sup>22</sup>. Administration of PAW may significantly decrease IFN- $\gamma$  ( $3.5 \pm 1.2$  pg/mL) and IL-2 ( $352.4 \pm 95.7$  pg/mL) production in ACI/NKyo rats after OAT for 90 days compared to ROW administered group. Moreover IFN- $\gamma$  expression almost reaches the basal level in PAW administered OAT ACI/NKyo rats. Based on these results, we predict that PAW may regulate alloimmunity and nonimmunity factors in an appropriate situation.

Table 2  
Comparison of OAT-induced Vasculopathy-related Proteins in ACI//NKyo Rats.

	Control ACI/NKyo (non-OAT)		OAT + ROW (PVG/Seac to ACI/NKyo)		OAT + PAW (PVG/Seac to ACI/NKyo)	
	baseline	90 days	baseline	90 days	baseline	90 days
<b>LDH (IU/L)</b>	900.5 ± 99.5	895.9 ± 125.6	854.6 ± 152.5	1888.78 ± 323.0 <sup>ab</sup>	802.3 ± 152.0	968.8 ± 116.4 <sup>c</sup>
<b>CRP (mg/dL)</b>	40.2 ± 13.5	39.6 ± 9.1	39.4 ± 9.8	163.5 ± 22.5 <sup>ab</sup>	26.5 ± 8.1	72.1 ± 5.4 <sup>abc</sup>
<b>HMGB1 (ng/mL)</b>	2.7 ± 1.4	2.8 ± 1.3	3.4 ± 1.5	98.7 ± 19.7 <sup>ab</sup>	2.5 ± 1.4	55.4 ± 13.1 <sup>abc</sup>
<b>SDF-1α (pg/mL)</b>	200.3 ± 22.6	196.5 ± 52.1	220.1 ± 41.5	432.6 ± 100.4 <sup>ab</sup>	241.3 ± 54.1	1211.4 ± 130.2 <sup>abc</sup>
<b>TGF-β1 (ng/mL)</b>	66.3 ± 21.2	78.9 ± 25.4	72.4 ± 19.7	378.1 ± 55.9 <sup>ab</sup>	72.1 ± 22.0	129.7 ± 54.1 <sup>abc</sup>
<b>INF-γ (pg/mL)</b>	2.5 ± 0.8	3.1 ± 0.9	1.5 ± 0.7	18.7 ± 5.3 <sup>ab</sup>	1.9 ± 0.8	3.5 ± 1.2 <sup>c</sup>
<b>IL-2 (pg/mL)</b>	45.7 ± 13.5	56.8 ± 18.9	53.7 ± 21.5	899.4 ± 102.4 <sup>ab</sup>	45.2 ± 21.0	352.4 ± 95.7 <sup>abc</sup>

OAT, orthotopic aortic transplantation; LDH, lactic dehydrogenase; CRP, C-reactive protein; HMGB1, high mobility group box 1 protein; INF-γ, interferon γ; TGF-β1, transforming growth factor- beta 1; SDF-1α, stromal cell-derived factor 1α; IL-2, interleukin 2; Values are represented as mean ± SD. <sup>a</sup>*p* < 0.05 compared with baseline of the same group; <sup>b</sup>*p* < 0.05 compared with control ACI/NKyo (non-OAT) group at the same time point; <sup>c</sup>*p* < 0.05 compared with OAT + ROW (PVG/Seac to ACI/NKyo) group at the same time point. Statistical evaluations were performed using one-way ANOVA.

### Administration of PAW results in reduced cell-mediated and humoral immune responses in OAT ACI/NKyo rats

Humoral and cell-mediated immunity are associated with the process of OAT-induced vasculopathy. Therefore, the spleens of experimental animals were analyzed by IHC to identify the severity of chronic rejection. CD11b positive macrophage, which is also an antigen-presenting cell, activates the adaptive immune system.<sup>23</sup> As shown in Fig. 3A, macrophages were barely observed in the germinal center (GC) and periarterial lymphatic sheath (PALS) of the spleen from naïve ACI/NKyo rat. In contrast, an increased number of macrophages appeared in the GC and PALS in the ROW administered group after OAT for 90 days. However, after 90 and 150 days of OAT, PAW administration significantly reduced the accumulation of macrophages in the GC and PALS. There are two major subtypes of T lymphocytes, helper T (Th) cells (CD4<sup>+</sup>) and killer T (Tc) cells (CD8<sup>+</sup>) involved in cell-mediated immunity. As shown in Fig. 3B, the GC and

PALS of spleen of naïve ACI/NKyo rats did not accumulate CD4 positive Th cells. In addition, rats in the OAT plus ROW group presented increased accumulation of CD4 positive Th cells in GC and PALS of spleen, which decreased upon PAW administration. Similar to CD4 positive Th cells, CD8 positive Tc cells also infiltrated into the PALS of spleen in OAT plus ROW ACI/NKyo rat, which was reversed upon PAW administration. Additionally, B cells (CD20<sup>+</sup>) mediate humoral immune responses and differentiates into plasma cells (CD138<sup>+</sup>) to produce antibodies. As shown in Fig. 3C, CD20 positive B cells predominantly cluster in the germinal center and mantle zone, and simultaneously, reduced number of plasma cells were observed in the germinal center, mantle zone, and venous sinuses of the spleen of naïve ACI/NKyo rat. ACI/NKyo rat with OAT plus ROW administration presented a large number of CD20 positive B cells accumulated in the germinal center and mantle zone, and activated plasma cells were observed at venous sinuses. In ACI/NKyo rat with OAT plus PAW administration, longer duration of PAW administration resulted in decreased accumulation of CD20 positive B cells in the germinal center and mantle zone. However, plasma cells were not observed in the venous sinuses, germinal center, and mantle zone. Based on these results, we predict that administration of PAW might maintain low levels of cell-mediated and humoral immune responses in ACI/NKyo rats.

### **Administration of PAW promotes increased mobilization of circulating EPCs and differentiation of early EPCs than administration of ROW in ACI/NKyo rats**

EPCs play an important role in repairing damaged vessels during the process of OAT <sup>24</sup>. As shown in Table 2, administering rats with PAW after OAT resulted in increased SDF-1 $\alpha$  and decreased TGF-1 $\beta$  as well as INF- $\gamma$  production in ACI/NKyo rats. SDF-1 $\alpha$  may mobilize circulating EPCs from the bone marrow <sup>25</sup>. TGF-1 $\beta$  is a guardian of T cell function <sup>26</sup> and may induce endothelial-mesenchymal transition (endo-MT) to ameliorate OAT-induced vasculopathy. INF- $\gamma$  expression plays an important role in the progression of OAT-induced vasculopathy <sup>27</sup>. Therefore, following OAT surgery, the population of endogenous EPCs (defined as CD133<sup>+</sup>/CD34<sup>+</sup>/VEGF<sup>+</sup> cells) and SMPCs (defined as CD133<sup>+</sup>/ $\alpha$ SMA<sup>+</sup>/CD34<sup>-</sup> cells) were quantified by flow cytometry, to compare the difference in levels of these cells between ROW and PAW administered ACI/NKyo rats. The results showed a significant increase in EPCs after 30 days of OAT in ROW administered ACI/NKyo rats compared to that of non-OAT ACI/NKyo rats, and this increase was maintained until day 90 after OAT (Fig. 4A). At day 30, OAT ACI/NKyo rats from the PAW administered group exhibited a significantly increased number of mobilized EPCs in the peripheral blood compared to that of OAT plus ROW group. However, the number of circulating EPCs was not associated with the time point after OAT in both ROW and PAW administered ACI/NKyo rats. Moreover, SMPCs initiated transplant arteriosclerosis. However, as shown by flow cytometry, the number of circulating SMPCs was not related to water administration, regardless of whether the animals received OAT (Fig. 4B).

The capacity of MNCs to form EPC colonies may represent the differentiation ability of circulating EPCs. As shown in Fig. 4C, the MNCs from ACI/NKyo rats seeded on fibronectin-coated wells on day 7 appeared to form early EPC colonies. MNCs from OAT ACI/NKyo rats administered with ROW and PAW also formed EPC colonies at 7 days of culture. The colonies of EPCs appearing on day 7 of culture presented as a

central core of round cells with elongated sprouting cells at the periphery. However, rats receiving PAW exhibited more efficient differentiation of MNCs. After 21 days of continuous culture, EPCs had cobblestone-like morphology similar to that of mature endothelial cells and were confluent in the PAW administered group. Conversely, the cells were sparse in the ROW administered group (Fig. 4C). These results indicated that PAW administration promotes increased mobilization and differentiation of early circulating EPCs than administration of ROW in OAT-recipient ACI/NKyo rats.

## Discussion

Water plays a vital role in all living entities and features as a solvent. In the human body, water functions as a medium for nutrient transfer and stabilizes body temperature levels. Additionally, water takes part in certain biochemical reactions, such as hydrolysis<sup>28</sup>, glycogen disintegration, and adenosine triphosphate disintegration<sup>29</sup>. Water, a widely utilized solvent, is typically considered inert in chain reactions. Nevertheless, water with its characteristic property of donor bridge acceptor for proton as well as electron transfer has been considered as an appealing energetic reactant<sup>30–32</sup>. Surface plasmon resonance causes excitation of AuNPs to decay into energized hot electrons. Hot electron transfer can promote numerous chemical reactions<sup>33</sup>, including dissociation of hydrogen<sup>34</sup>, activation of oxygen<sup>35</sup>, as well as electrocatalytic hydrogen evolution<sup>36</sup>. Our group proposed an innovative method to create PAW, which is prepared by treating ROW with resonantly excited AuNPs<sup>10,37,38</sup>. Recently, we have demonstrated that PAW is innovatively applicable in various fields<sup>39</sup>. PAW with its unique properties of enhancing solute diffusion as well as exhibiting anti-inflammatory properties considerably shortens the time required to remove uremic contaminants during hemodialysis therapy<sup>11,40</sup>. Additionally, PAW decreased fibronectin expression and renal fibrosis in mice with chronic kidney disease<sup>40</sup>, and reduced liver damage in chronic sleep-deprived rats<sup>41</sup>. Compared to mice administered with ROW, PAW administration may improve the survival time and cisplatin effect in Lewis lung carcinoma cells-bearing mice, and may be associated with inducing Nrf2 gene expression<sup>14</sup>. A previous study suggests that PAW has potential therapeutic effects against Parkinson's disease, periodontal disease, and Alzheimer's disease<sup>15</sup>.

After organ transplantation, once the immune and inflammatory responses are activated by alloimmune-, autoimmune-, or non-immune factors, the fibrotic changes that occur in the arteries of the graft results in OAT-induced vasculopathy, which subsequently causes ischemia<sup>42</sup>. Endothelium muscularization and intimal hyperplasia can be observed in most transplanted organs<sup>43</sup>. However, endo-MT refers to the process of differentiation of endothelial cells into interstitial cells (such as smooth muscle cells and fibroblasts)<sup>44</sup>, which has been considered to be associated with the occurrence of OAT-induced vasculopathy<sup>44–46</sup>. A previous report has demonstrated that smooth muscle cell (SMCs) proliferation, mobilization and differentiation of circulating EPCs, and endo-MT co-regulate the process of OAT-induced vasculopathy. The arteries of OAT-induced vasculopathy indicate the presence of SMCs which are mostly derived from the donor<sup>47</sup> and are activated and proliferate following inflammatory responses. These cells exhibit chemotaxis moving from the media to the intima of the vessel<sup>9</sup>. In addition, donor-derived

SMCs at the lesion originate from donor-derived ECs formed via endo-MT<sup>48</sup>. In recipients, bone marrow-derived CD133<sup>+</sup>/CD34<sup>+</sup>/VEGF-R1<sup>+</sup> EPCs and circulating CD31<sup>+</sup>/CD146<sup>+</sup>/vWF<sup>+</sup>/NOS<sup>+</sup> EPCs have the characteristics of endothelial regenerative properties<sup>49–51</sup>. However, recent studies have found that recipient's EPCs are, instead, involved in the pathological process of vasculopathy<sup>5, 50, 52</sup> due to the fact that circulating EPCs will adhere to the arterial endothelium and begin to proliferate, and induce persistent allogeneic immune responses<sup>52</sup>. In addition, EPCs will uncontrollably accumulate and induce massive proliferation of SMCs, and the proliferating SMCs will secrete large amounts of extracellular matrix proteins to cause intimal hyperplasia<sup>50</sup>. Therefore, scientists speculate that despite the recipient exhibiting vigorous mobilization of EPCs, the persistent and uncontrolled allogeneic immune response may activate endo-MT and stimulate EPCs to differentiate into SMCs, which finally causes vasculopathy<sup>52–54</sup>. The TGF- $\beta$  signaling pathway is closely associated with the induction of fibrosis<sup>44, 55</sup>. In our study, we found that OAT increases the plasma level of SDF-1 $\alpha$  (Table 2) as well as the number of circulating EPCs in ACI/NKyo rats. However, PAW administered ACI/NKyo rats had higher concentration of plasma SDF-1 $\alpha$  and increased number of circulating EPCs compared to ROW administered rats (Fig. 4A). Although TGF- $\beta$ 1 is the major factor that induces endo-MT, the plasma TGF- $\beta$ 1 concentration in OAT-ACI/NKyo rats fed with PAW was lower than that of the ROW fed group. Moreover, the decrease in circulating SMCs in the PAW group was not statistically significant. We speculate that PAW may induce increased mobilization of EPCs from the bone marrow by increasing plasma SDF-1 $\alpha$  concentration. On the other hand, PAW also reduces TGF- $\beta$ 1, including TGF- $\beta$ 1-mediated endo-MT which may be the possible mechanism of reducing OAT-induced vasculopathy. Endo-MT is regulated by complex molecular mechanisms. TGF- $\beta$ 1 and TGF- $\beta$ 2 promote endo-MT<sup>54, 56</sup>. When endo-MT is induced by TGF- $\beta$ , bone morphogenetic protein (BMP) and activin receptor-like kinase, regulate gene expression through phosphorylation of SMAD [60]. The phosphorylated SMAD enters the nucleus and interacts with key transcription factors that regulate endo-MT such as SNAI1, SNAI2, ZEB1, ZEB2, KLF4, TCF3, and TWIST which ultimately leads to chromatin rearrangement and endo-MT-related gene expression<sup>57</sup>. In addition to TGF- $\beta$  mainly activating SMAD to initiate the process of endo-MT, it may activate other complementary pathways including mitogen-activated protein kinase pathway, phosphoinositide 3-kinase pathway, and inhibit the microRNA pathway that are all related to endo-MT. Therefore, we further intend to analyze the molecular mechanisms involved in PAW-induced inhibition of endo-MT.

In this study, we also analyzed the effect of PAW on the plasma levels of IFN- $\gamma$ , HMGB1, and IL-2 in OAT-recipient rats. It is well known that IFN- $\gamma$  expression is associated with activation, differentiation, and recruitment of T-cells via direct or indirect signaling pathways<sup>58, 59</sup>, which mediate OAT-induced vasculopathy. In 2016, Van Loosdregt and colleagues demonstrated that patients with transplanted heart vasculopathy had higher levels of IFN- $\gamma$ , IFN- $\gamma$ -inducible chemokines (fractalkine/CX3CL1, RANTES, ITAC, and IP-10), and IFN- $\gamma$ -secreting Th1 cell markers (CXCR3, CCR5, and CX3CR1) in coronary arteries compared to control individuals<sup>60</sup>. Additionally, the nuclei of necrotic cells may release HMGB1<sup>61</sup>; the mature antigen-presenting cells and macrophages are stimulated by IFN- $\gamma$  or TNF- $\alpha$  to secrete HMGB1<sup>62, 63</sup>. In macrophages, the secretion of HMGB1 induces hyperacetylation of the protein<sup>64</sup> and increases the

ability to participate in adaptive alloimmune rejection. HMGB1 may activate the differentiation of Th1 cells via receptor for advanced glycation end-products (RAGE)<sup>62, 65</sup>. Stimulated endothelial cells in the vessel wall also produce HMGB1, and subsequently activate more endothelial cells and amplify the inflammatory responses<sup>66, 67</sup>. Moreover, injury-induced mediators, such as IL-1 and C5a may affect IFN- $\gamma$  production and differentiation of Th1 cells. In general, the primary damage caused due to rejection may provoke a greater adaptive alloimmune response through specific mediators, thereby inducing T cells to produce increased IFN- $\gamma$  and OAT-induced vasculopathy-related proteins, which ultimately leads to vasculopathy. In this study, we observed that administering PAW could reduce the plasma IFN- $\gamma$  concentration in OAT-ACI/NKyo rats to almost similar levels as that of control ACI/NKyo rats. Although HMGB1 expression did not decrease to the baseline level, it was significantly lower than the levels in ROW administered OAT-ACI/NKyo rats. We speculate that PAW can effectively modulate the adaptive alloimmune response after OAT by modifying the expression of IFN- $\gamma$ . However, since tissue damage and immune responses after OAT are caused by multiple immune factors, administering PAW can only partially reduce HMGB1 production in OAT-ACI/NKyo rats. In the future, we consider using PAW in combination with existing clinical drugs to develop effective therapeutic strategies for OAT-induced vasculopathy.

In this study, although we only explored the effects of PAW on OAT-induced vasculopathy and obtained surprising results, we continue to study its detailed mechanism of action. Since drinking water is a natural activity that must be carried out in the life of human beings, if drinking PAW only as a treatment method, it will inevitably not be convinced by most people. Therefore, without deviating from the current focus on prevention and treatment of OAT-induced vasculopathy, we are initiating a study to elucidate the synergistic effects of PAW on anti-rejection and immunomodulatory agents, and analyze whether the use of PAW in combination with existing drugs can achieve better therapeutic effects than current treatment modalities. Overall, this study indicated that daily consumption of PAW might decrease the progress of vasculopathy in OAT-recipient ACI/NKyo rats by promoting the inhibition collagen accumulation, SMC and fibroblast infiltration, and Tc and Th cell responses in the vessel walls. Furthermore, the data showed reduced activation of T lymphocytes, B lymphocytes, plasma cells, and macrophages in the spleen of PAW administered OAT-recipient ACI/NKyo rats compared to ROW administered OAT-recipient ACI/NKyo rats. Finally, we observed higher mobilization and levels of circulating EPCs in PAW-administered OAT-recipient ACI/NKyo rats compared to control group. Therefore, this study highlights the potential therapeutic roles of PAW in OAT-induced vasculopathy.

## Methods

### Animals

A statement confirming the study was carried out in compliance with the ARRIVE guidelines. All animals were treated according to the protocols approved by the Institutional Animal Care Committee of the National Defense Medical Center (certificate Nos. IACUC-20-275). Experimental procedures and animal

care conformed to the “Guide for the Care and Use of Laboratory Animals” published by the U.S. National Institutes of Health (NIH Publication No. 85 – 23, revised 1996).

Full Methods are available in the supplementary of the paper.

## Declarations

### Acknowledgements

We thank Long-Ji Lin and Ya-Yu Chan for excellent technical assistance. This work was supported by Tri-service General Hospital (TSGH-C02-109020 and TSGH-C02-109023) and Taipei Medical University (109TMU-TMUH-08) in Taiwan.

### Author Contributions

Y.T.T., Y.W.L., and F.Y.L. conceived of the project, designed and performed experiments and analyzed the data. Y.C.L. provided device of PAW production and maintained the quality of PAW. C.S.T., C.M.S., C.Y.H., S.J.L., and C.Y.L. contributed with regard to reagents/materials/analysis tools/consultant. C.Y.L. and Y.T.T. contributed to the statistical analyses. This manuscript was written by Y.W.L. and F.Y.L. All authors reviewed and approved the final version of the manuscript.

**Competing Interests:** The authors declare no competing interests.

## References

1. Lund, L. H., Edwards, L. B., Kucheryavaya, A. Y., Dipchand, A. I., Benden, C., *et al.* The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report–2013; focus theme: age. *J Heart Lung Transplant* **32**, 951–964 (2013).
2. Costello, J. P., Mohanakumar, T. and Nath, D. S. Mechanisms of chronic cardiac allograft rejection. *Tex Heart Inst J* **40**, 395–399 (2013).
3. Nath, D. S., Basha, H. I. and Mohanakumar, T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. *Curr Opin Organ Transplant* **15**, 16–20 (2010).
4. Kaczmarek, I., Deutsch, M. A., Kauke, T., Beiras-Fernandez, A., Schmoeckel, M., *et al.* Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. *Exp Clin Transplant* **6**, 229–235 (2008).
5. Weiss, M. J., Madsen, J. C., Rosengard, B. R. and Allan, J. S. Mechanisms of chronic rejection in cardiothoracic transplantation. *Front Biosci* **13**, 2980–2988 (2008).
6. Daly, K. P., Seifert, M. E., Chandraker, A., Zurakowski, D., Nohria, A., *et al.* VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. *J Heart Lung Transplant* **32**, 120–128 (2013).



7. Benatti, R. D. and Taylor, D. O. Evolving concepts and treatment strategies for cardiac allograft vasculopathy. *Curr Treat Options Cardiovasc Med* **16**, 278 (2014).
8. Zhang, Q., Cecka, J. M., Gjertson, D. W., Ge, P., Rose, M. L., *et al.* HLA and MICA: targets of antibody-mediated rejection in heart transplantation. *Transplantation* **91**, 1153–1158 (2011).
9. Pober, J. S., Jane-wit, D., Qin, L. and Tellides, G. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. *Arterioscler Thromb Vasc Biol* **34**, 1609–1614 (2014).
10. Chen, H. C., Hwang, B. J., Mai, F. D., Liu, Y. C., Lin, C. M., *et al.* Active and stable liquid water innovatively prepared using resonantly illuminated gold nanoparticles. *ACS Nano* **8**, 2704–2713 (2014).
11. Chen, H. C., Lin, H. C., Chen, H. H., Mai, F. D., Liu, Y. C., *et al.* Innovative strategy with potential to increase hemodialysis efficiency and safety. *Sci Rep* **4**, 4425 (2014).
12. Yang, C. P., Chen, H. C., Wang, C. C., Tsai, P. W., Ho, C. W., *et al.* Effective Energy Transfer via Plasmon-Activated High-Energy Water Promotes Its Fundamental Activities of Solubility, Ionic Conductivity, and Extraction at Room Temperature. *Sci Rep* **5**, 18152 (2015).
13. Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P. and Malik, A. B. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal* **20**, 1126–1167 (2014).
14. Wang, C. K., Chen, H. C., Fang, S. U., Ho, C. W., Tai, C. J., *et al.* Innovatively Therapeutic Strategy on Lung Cancer by Daily Drinking Antioxidative Plasmon-Induced Activated Water. *Sci Rep* **8**, 6316 (2018).
15. Cheng, C. H., Lin, K. J., Hong, C. T., Wu, D., Chang, H. M., *et al.* Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory in Animals with Alzheimer's Disease. *Sci Rep* **9**, 13252 (2019).
16. Kato, G. J., Hebbel, R. P., Steinberg, M. H. and Gladwin, M. T. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. *Am J Hematol* **84**, 618–625 (2009).
17. Khan, T. T., Mirza, A. B., Zahid, R., Haleem, A., Al Hussaini, H., *et al.* Antibody-mediated rejection: importance of lactate dehydrogenase and neutrophilia in early diagnosis. *Saudi J Kidney Dis Transpl* **22**, 525–530 (2011).
18. Sproston, N. R. and Ashworth, J. J. Role of C-Reactive Protein at Sites of Inflammation and Infection. *Front Immunol* **9**, 754 (2018).
19. Zou, H., Yang, Y., Gao, M., Zhang, B., Ming, B., *et al.* HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs. *Am J Transplant* **14**, 1765–1777 (2014).
20. Fadini, G. P., Sartore, S., Albiero, M., Baesso, I., Murphy, E., *et al.* Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. *Arterioscler Thromb Vasc Biol* **26**, 2140–2146 (2006).
21. Pintavorn, P. and Ballermann, B. J. TGF-beta and the endothelium during immune injury. *Kidney Int* **51**, 1401–1412 (1997).

22. Weis, M., Wildhirt, S. M., Schulze, C., Pehlivanli, S., Fraunberger, P., *et al.* Modulation of coronary vasomotor tone by cytokines in cardiac transplant recipients. *Transplantation* **68**, 1263–1267 (1999).
23. Rua, R. and McGavern, D. B. Elucidation of monocyte/macrophage dynamics and function by intravital imaging. *J Leukoc Biol* **98**, 319–332 (2015).
24. Del Papa, N. and Pignataro, F. The Role of Endothelial Progenitors in the Repair of Vascular Damage in Systemic Sclerosis. *Front Immunol* **9**, 1383 (2018).
25. Tilling, L., Chowienczyk, P. and Clapp, B. Progenitors in motion: mechanisms of mobilization of endothelial progenitor cells. *Br J Clin Pharmacol* **68**, 484–492 (2009).
26. Oh, S. A. and Li, M. O. TGF-beta: guardian of T cell function. *J Immunol* **191**, 3973–3979 (2013).
27. Knight, R. J., Liu, H., Fishman, E. and Reis, E. D. Cold ischemic injury, aortic allograft vasculopathy, and pro-inflammatory cytokine expression. *J Surg Res* **113**, 201–207 (2003).
28. Slaughter, S. L., Ellis, P. R., Jackson, E. C. and Butterworth, P. J. The effect of guar galactomannan and water availability during hydrothermal processing on the hydrolysis of starch catalysed by pancreatic alpha-amylase. *Biochim Biophys Acta* **1571**, 55–63 (2002).
29. de Meis, L. and Suzano, V. A. Role of water activity on the rates of acetyl phosphate and ATP hydrolysis. *FEBS Lett* **232**, 73–77 (1988).
30. Rivard, U., Thomas, V., Bruhacs, A., Siwick, B. and Iftimie, R. Donor-Bridge-Acceptor Proton Transfer in Aqueous Solution. *J Phys Chem Lett* **5**, 3200–3205 (2014).
31. Mifsud, M., Gargiulo, S., Iborra, S., Arends, I. W., Hollmann, F., *et al.* Photobiocatalytic chemistry of oxidoreductases using water as the electron donor. *Nat Commun* **5**, 3145 (2014).
32. Ricci, M., Spijker, P. and Voitchovsky, K. Water-induced correlation between single ions imaged at the solid-liquid interface. *Nat Commun* **5**, 4400 (2014).
33. Guo, J., Zhang, Y., Shi, L., Zhu, Y., Mideksa, M. F., *et al.* Boosting Hot Electrons in Hetero-superstructures for Plasmon-Enhanced Catalysis. *J Am Chem Soc* **139**, 17964–17972 (2017).
34. Mukherjee, S., Libisch, F., Large, N., Neumann, O., Brown, L. V., *et al.* Hot electrons do the impossible: plasmon-induced dissociation of H<sub>2</sub> on Au. *Nano Lett* **13**, 240–247 (2013).
35. Huang, Y. F., Zhang, M., Zhao, L. B., Feng, J. M., Wu, D. Y., *et al.* Activation of oxygen on gold and silver nanoparticles assisted by surface plasmon resonances. *Angew Chem Int Ed Engl* **53**, 2353–2357 (2014).
36. Zhang, H. X., Li, Y., Li, M. Y., Zhang, H. and Zhang, J. Boosting electrocatalytic hydrogen evolution by plasmon-driven hot-electron excitation. *Nanoscale* **10**, 2236–2241 (2018).
37. Chen, H. C., Mai, F. D., Yang, K. H., Chen, L. Y., Yang, C. P., *et al.* Quantitative evaluation on activated property-tunable bulk liquid water with reduced hydrogen bonds using deconvoluted Raman spectroscopy. *Anal Chem* **87**, 808–815 (2015).
38. Chen, H. C., Mai, F. D., Hwang, B. J., Lee, M. J., Chen, C. H., *et al.* Creation of Electron-doping Liquid Water with Reduced Hydrogen Bonds. *Sci Rep* **6**, 22166 (2016).


39. Yang, C. P. and Liu, Y. C. Therapeutics for Inflammatory-Related Diseases Based on Plasmon-Activated Water: A Review. *Int J Mol Sci* **19**, (2018).
40. Chen, H. C., Cheng, C. Y., Lin, H. C., Chen, H. H., Chen, C. H., *et al.* Multifunctions of Excited Gold Nanoparticles Decorated Artificial Kidney with Efficient Hemodialysis and Therapeutic Potential. *ACS Appl Mater Interfaces* **8**, 19691–19700 (2016).
41. Gonzalez-Ortegon, E., Vay, L. L., Walton, M. E. M. and Gimenez, L. Maternal Trophic Status and Offspring Phenotype in a Marine Invertebrate. *Sci Rep* **8**, 9618 (2018).
42. Huibers, M., De Jonge, N., Van Kuik, J., Koning, E. S., Van Wichen, D., *et al.* Intimal fibrosis in human cardiac allograft vasculopathy. *Transpl Immunol* **25**, 124–132 (2011).
43. Rahmani, M., Cruz, R. P., Granville, D. J. and McManus, B. M. Allograft vasculopathy versus atherosclerosis. *Circ Res* **99**, 801–815 (2006).
44. Chen, P. Y., Qin, L., Barnes, C., Charisse, K., Yi, T., *et al.* FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. *Cell Rep* **2**, 1684–1696 (2012).
45. Kovacic, J. C., Mercader, N., Torres, M., Boehm, M. and Fuster, V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. *Circulation* **125**, 1795–1808 (2012).
46. von Gise, A. and Pu, W. T. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. *Circ Res* **110**, 1628–1645 (2012).
47. Atkinson, C., Horsley, J., Rhind-Tutt, S., Charman, S., Phillpotts, C. J., *et al.* Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. *J Heart Lung Transplant* **23**, 427–435 (2004).
48. Borthwick, L. A., Parker, S. M., Brougham, K. A., Johnson, G. E., Gorowiec, M. R., *et al.* Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. *Thorax* **64**, 770–777 (2009).
49. Hillebrands, J. L., Onuta, G. and Rozing, J. Role of progenitor cells in transplant arteriosclerosis. *Trends Cardiovasc Med* **15**, 1–8 (2005).
50. Hillebrands, J. L., Klatter, F. A. and Rozing, J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. *Arterioscler Thromb Vasc Biol* **23**, 380–387 (2003).
51. D'Alessandro, D. A., Kajstura, J., Hosoda, T., Gatti, A., Bello, R., *et al.* Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart. *Circ Res* **105**, 1128–1140 (2009).
52. Sathya, C. J., Sheshgiri, R., Prodger, J., Tumiaty, L., Delgado, D., *et al.* Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients. *Transpl Int* **23**, 641–648 (2010).
53. Simper, D., Wang, S., Deb, A., Holmes, D., McGregor, C., *et al.* Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of

- noncardiac origin are enriched in transplant atherosclerosis. *Circulation* **108**, 143–149 (2003).
54. Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., *et al.* Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. *Nat Med* **13**, 952–961 (2007).
55. Piera-Velazquez, S. and Jimenez, S. A. Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. *Fibrogenesis Tissue Repair* **5**, S7 (2012).
56. Evrard, S. M., Lecce, L., Michelis, K. C., Nomura-Kitabayashi, A., Pandey, G., *et al.* Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. *Nat Commun* **7**, 11853 (2016).
57. Derynck, R. and Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* **425**, 577–584 (2003).
58. Tellides, G. and Pober, J. S. Interferon-gamma axis in graft arteriosclerosis. *Circ Res* **100**, 622–632 (2007).
59. Bolinger, B., Engeler, D., Krebs, P., Miller, S., Firner, S., *et al.* IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8 + T-cell-mediated injury of vascular endothelial cells. *Eur J Immunol* **40**, 733–743 (2010).
60. van Loosdregt, J., van Oosterhout, M. F., Bruggink, A. H., van Wichen, D. F., van Kuik, J., *et al.* The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. *Circulation* **114**, 1599–1607 (2006).
61. Lotze, M. T. and Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol* **5**, 331–342 (2005).
62. Messmer, D., Yang, H., Telusma, G., Knoll, F., Li, J., *et al.* High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. *J Immunol* **173**, 307–313 (2004).
63. Rendon-Mitchell, B., Ochani, M., Li, J., Han, J., Wang, H., *et al.* IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. *J Immunol* **170**, 3890–3897 (2003).
64. Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., *et al.* Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. *EMBO J* **22**, 5551–5560 (2003).
65. Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., *et al.* Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. *J Biol Chem* **279**, 7370–7377 (2004).
66. Treutiger, C. J., Mullins, G. E., Johansson, A. S., Rouhiainen, A., Rauvala, H. M., *et al.* High mobility group 1 B-box mediates activation of human endothelium. *J Intern Med* **254**, 375–385 (2003).
67. Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., *et al.* Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. *Blood* **101**, 2652–2660 (2003).

# Figures



(figure 1AB)




(figure 2C)

## Figure 1

Administration of PAW in OAT ACI/NKyo rats resulted in reduced allograft vasculopathy. (A) Representative photographs of vasculopathy in thoracic aortas (from donor PVG/Seac rats) stained with H&E. The arrowheads indicate calcified lesions and arrows indicate internal elastic lamina. (B) The


graphs represent the ratio of intimal and vessel wall areas in the aortas from the five experimental groups. The images are 40x magnified. The results are expressed as the mean $\pm$ SEM. Statistical evaluations were performed using the Student t-test, followed by Dunnett's test. \*p < 0.05 was considered as significant. (C) Histopathological features of thoracic aorta cross-sections were observed using picrosirius red staining. The slides were observed via polarized light microscopy (200x magnification).



(figure 2)

Figure 2


Administration of PAW is effective against SMCs, fibroblasts, CD4+ T lymphocytes, CD8+ T lymphocytes and macrophage activity in OAT-induced chronic allograft vasculopathy. (A) Immunohistochemistry to assess proliferated SMCs ( $\alpha$ SMA) and accumulated fibroblasts (S100A4) in rat thoracic aortas from donor PVG/Seac rats. The lumen is uppermost in all sections; the images are 200x magnified. Similar regions are shown as enlarged images (400x magnification) in the upper left corners. The brown signal indicates  $\alpha$ SMA- and S100A4-positive cells. (B) Immunohistochemistry to analyze accumulated helper T cells (CD4), cytotoxic T cells (CD8) and infiltrated macrophages (CD11b) in rat thoracic aortas from donor PVG/Seac rats. The images are 200x magnified. Similar regions are shown as enlarged images (400x magnification) in the lower left corners. The brown signal indicates CD4-, CD8- and CD11b-positive cells. Semi-quantification of immunohistochemically positive stained cells in high power field (HPF) is shown in the right panel of figures A and B. The graphs represent the accumulation of cells in the aortas of rats from the experimental groups. The results are expressed as the mean  $\pm$  SEM. Statistical evaluations were performed using Student t-test, followed by Dunnett's test. \* $p < 0.05$  was considered as significant.



### Figure 3

Decreased activity of macrophages, T lymphocytes, B lymphocytes, and plasma cells in the spleen of PAW administered OAT-ACI/NKyo rats. (A) Immunohistochemistry was performed to assess the accumulated macrophages (CD11b) in the spleen of OAT-recipient ACI/NKyo rats (GC, germinal center; PALS, periarterial lymphatic sheath; CA, central artery). The brown signals indicated by triangle arrow heads are CD11b-positive macrophages. The images in the upper column are 200x magnified and the

square regions are shown as enlarged images (400x magnification) in the lower column. (B) Immunohistochemistry was performed to analyze accumulated helper T cells (CD4) and cytotoxic T cells (CD8) in the spleen of OAT-recipient ACI/NKyo rats. The images are 200x and 400x magnified, respectively. The brown signal indicated by triangle arrow heads are CD4- and CD8-positive cells. (C) Immunohistochemical analysis of accumulated B cells (CD20) and activated plasma cells (CD138) in the spleen of OAT-recipient ACI/NKyo rats (MZ, mantle zone; VS, venous sinuses). The images are 200x and 400x magnified, respectively. The brown signals indicated by triangle arrow heads are CD138-positive cells. The cell nuclei were stained with hematoxylin and the slides were observed via light microscopy.



(figure 4)

Figure 4

Administration of PAW promotes mobilization of circulating EPCs and differentiation of early EPCs in OAT-recipient ACI/NKyo rats. (A and B) EPC (defined as CD133+/CD34+/VEGF+ cells) and SMPC (defined as CD133+/ $\alpha$ SMA+/CD34- cells) mobilization at day 30, 60, and 90 following OAT in ACI/NKyo rats was determined by flow cytometry. Quantification of EPCs (left) and SMPCs in OAT-recipient rats (black bar, control group; light gray bar, OAT plus ROW administered group; white bar, OAT plus ROW administration group). (C) At the end of the experiment (90th day), MNCs from ACI/NKyo rats were seeded on 6-well plates. Cells were incubated with EGM-2 medium and observed every three days under a microscope beginning on day 7 after seeding the cells. Images at 200x magnification on day 7 and day 21 of cultured cells are shown. Arrows indicate the total EPC colony forming units (CFUs) over 7 days. Right graphs show the number of EPC CFUs ( $5 \times 10^5$  MNCs/well in a 6-well plate) over 7 days, and late EPC numbers in  $5 \times 10^5$  MNCs cultured over 21 days in the different groups. All results are expressed as the mean  $\pm$  SD (n=5). Statistical evaluations were performed using Student t-test, followed by Dunnett's test.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Tables.docx](#)
- [Onlinedata.docx](#)